[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100182531":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":10,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":37,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A",null,"Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744\u002F085).",[13],"Procedure: Serum sample",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B","Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503\u002F048).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"PROCEDURE","Serum sample","Serum samples collected at pre-determined time points in previously completed studies (217744\u002F085 and 213503\u002F048) will be analysed to detect the presence of anti PCV-1 antibodies.",[9,15],[25],{"name":26,"affiliation":5,"role":27},"GSK Clinical Trials","STUDY_DIRECTOR",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100182531","assessment-of-the-serologic-response-to-porcine-circovirus-type-1-pcv-1-in-the-serum-of-infants-and-toddlers-following-administration-of-ipv-inactivated-poliovirus-vaccine-containing-vaccines-100182531",false,"NCT01651247","Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines","Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants Aged 2 and 6 Months and Toddlers Aged 4-6 Years Following Administration of GlaxoSmithKline (GSK) Biologicals' IPV-containing Vaccines","Inclusion Criteria:\n\n* Subjects enrolled previously in randomized, open and multicentre studies \\[217744\u002F085; 213503\u002F048\\].\n* Subjects aged 6 months to 6 years at last dose vaccinated with either DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines or DTaP-IPV vaccine or separately administered DTaP and IPV vaccines.\n* Subjects for whom sufficient residual volume of the pre and post vaccination blood samples is available.\n\nExclusion Criteria:\n\n* Not Applicable",true,"ALL","2 Months","6 Years",{"count":42,"type":43},1,"ACTUAL","OBSERVATIONAL","This study aims to analyse the serologic response to PCV-1 in the PEDIARIX® \\[GSK Biologicals' Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine\\] and KINRIX® (GSK Biologicals' Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) vaccine products. The samples have been collected at pre-determined time points from a subset of subjects who participated in selected studies \\[217744\u002F085 and 213503\u002F048\\] conducted in the United States.",[47],"Presence of Materials From PCV-1",[49,50,51,52,53,54],"Toddlers","Retrospective","Porcine circovirus type 1 (PCV-1)","Infants","Laboratory evaluations","IPV","COMPLETED","2012-07-24",{"date":58,"type":59},"2012-07-27","ESTIMATED",{"date":61,"type":10},"2010-05",{"date":61,"type":43},{"name":5,"class":6}]